Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (279)	2/11/2003 12:59:56 PM
From: Jibacoa	of 3722

LGND May be finding support at the 4 level.<g> At a meeting yesterday it was reported that treatment with LGND's ONTAK was able to achieve remission in 5 of 11 patients with acute GVHD, and another 2 patients had a partial remission, for an overall response rate of 64%(seven of 11 patients). Of course back in December at the ASH meeting it was already reported good results of ONTAK on GVHD as well as on CLL and NHL.(ONTAK has already been approved by the FDA since Feb.1999 for treatment of patients with persistent or recurrent CTCL who express the p55 (CD25) component of the IL-2 receptor.) And LGND's Targretin,which also received FDA approval for for the treatment of cutaneous manifestations of CTCL in December 1999 and is on phase III trials as oral treatment for NSCLC and has also shown to be able to "dramatically reduce" <g> the development of ER negative mammary tumors in mice . And GSK has begun human trials of SB-497115 for thrombocytopenia. (There are no approved TPO agents for the treatment or prevention of thrombocytopenia and LGND believes that its small molecule oral drug that mimics TPO with no apparent immunogenic side effects will provide therapy for a major unmet medical need.<g> In view of LGND's good pipeline and its collaboration with important large corporate partners in products with large market indications like osteoporosis, diabetes,CVD, oncology and contraception it seems the R/R is favorable at present levels.<g> siliconinvestor.com siliconinvestor.com Of course LGND shares need to close its Nov.13 down-gap and will look much better if they can close above 7.<g> siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next